Overactive Bladder
Conditions
Keywords
Overactive Bladder, Vaginal Estrogen, Anticholinergics, Antimuscarinics
Brief summary
The use of vaginal estrogen cream in conjunction with Toviaz will be more effective than the use of Toviaz alone for the treatment of overactive bladder.
Detailed description
Participants will be randomized to two treatment arms with 45 patients enrolled in each study arm: Toviaz and Premarin Vaginal Cream and Toviaz and Placebo Premarin Vaginal Cream. The Toviaz will be dosed at 4mg tablet given as a once daily dose. Premarin vaginal cream will be dosed at 1 gram per vagina twice weekly. Compliance will be assessed at the 4-week mark and again at completion of the study, 8 weeks after the commencement of treatment. The questionnaires chosen for this study have been designed and validated as effective tools to assess and evaluate OAB. Patients will be asked to complete three symptoms questionnaires and a 3-day voiding dairy. The questionnaires include Overactive Bladder Questionnaire (OAB-q), The Patient Perception of Bladder Condition, and Urgency Severity and Impact Questionnaire. The voiding diary and questionnaires will be filled out and collected at the initial visit and again at the end of the study which is defined as 8 weeks after the commencement of treatment. Additionally, patients will be asked to rate their symptoms associated with urogenital atrophy at the start of the study and then again at 8 weeks. The severity of each symptom will be graded based on a four-point scale (0=none, 1=mild, 2= moderate, 3=severe) and a composite score will then be generated. Examiners will also rate the severity of signs of urogenital atrophy at the first visit and at the conclusion of the study. An objective evaluation of the effectiveness of the estrogen cream treatment will be accomplished by a pathological evaluation of the vaginal cell samples at the beginning of treatment and then again at the 8 week point. These cells will be collected and analyzed by an independent pathologist to determine the percentage of parabasal, intermediate, and superficial cells and to document the change in these three categories of cells as a result of the vaginal estrogen treatment. A 3-Day voiding diary will be used to document changes from baseline for urinary urgency, frequency, and incontinence episodes. Based on previous studies we predict there will be a 45% improvement on urinary frequency from baseline when using both Toviaz and vaginal Premarin cream. Secondary outcomes will be measured using the following validated questionnaires given at the start of the study and again at completion: OAB-q, Patient Perception of Bladder Condition, Urgency Severity and Impact Questionnaire.
Interventions
Sponsors
Pfizer
The Cleveland Clinic
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
30 Years to 100 Years
Healthy volunteers
Yes
Inclusion criteria
* Postmenopausal Women defined as at least 12 months since last menstrual period * OAB symptoms for 6 months or longer with complaints of frequency (8 or more voids in a 24 hour period), and either 6 or more urgency episodes in 24 hours, and either 3 or more urge urinary incontinence episodes per 24 hours.
Exclusion criteria
* Current or recent treatment (within the last 6 months) with estrogens * Past or present history of estrogen dependent neoplasm * Undiagnosed genital tract bleeding * Current urinary or vaginal infection * History of thromboembolic disorders associated with estrogen use * Commencement or alteration of diuretic therapy within three months of study enrollment * No contraindications for anticholinergic medical therapy * No contraindications to estrogen therapy * Symptoms must not have commenced more than three years prior to menopause * Post Void Residual must be under or equal to 150 ml * Recurrent Urinary Tract Infections (3 culture proven UTI's within the past 12 months) * Not on any other anticholinergic medications for the last 4 weeks * Painful Bladder Syndrome * Chronic Pelvic Pain * Vaginal Prolapse POPQ \> stage 2/ maximal prolapse point greater than +1 cm
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Urinary frequency as measured by a 3 day voiding diary | 1 year | number of voids per day |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Lifestyle Impact of Overactive Bladder as measured using 3 validated questionnaires: OAB-Q, PPBC, and Urgency Severity and Impact Questionnaire | 1 year | quality of life assessment via questionnaire |
Countries
United States
Contacts
Primary ContactAlexandriah Alas, MD
Backup ContactEric Hurtado, MD
Outcome results
None listed